Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature

被引:5
作者
Alshareefy, Yasir [1 ]
Shen, Chai Yu [2 ]
Prekash, Rosheene Jeya [2 ]
机构
[1] Univ Dublin, Trinity Coll Dublin, Sch Med, Dublin, Ireland
[2] Manipal Univ Coll, Dept Med, Melaka, Malaysia
关键词
Liver pathology; Molecular pathology; Tumour pathology; Cancer; COPPER-BINDING PROTEIN; BUDD-CHIARI-SYNDROME; LIVER; EXPRESSION; FEATURES; SURVIVAL; VARIANT; TUMOR; GYNECOMASTIA; CAPACITY;
D O I
10.1016/j.prp.2023.154655
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This paper aims to present a detailed overview of fibrolamellar carcinoma (FLC), a variant of hepatocellular carcinoma (HCC) that accounts for approximately 1-9% of all cases a. according to the SEER database. Despite ongoing research, the aetiology of FLC tumours remains unclear. Nevertheless, FLC is believed to have a better overall prognosis than other primary liver tumours, such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma. This study aims to present a comprehensive overview of fibrolamellar carcinoma (FLC), with a focus on its epidemiology, pathogenesis, diagnosis, treatment, and prognosis. FLC frequently incorporate features of stomach pain, weight loss, and malaise in their clinical signs and symptoms, which are generally nonspecific Ultimately, the most common physical finding is an abdominal mass or hepatomegaly. With this said, several unusual presentations have been documented such as Budd Chiari syndrome, severe anaemia, nonbacterial thrombotic endocarditis and many more. In regards to this tumour's genetic analysis, it is characterised by a 400 kb deletion on chromosome 19 leading to a functional DNAJB1-PRKACA chimeric transcript in addition to tetraploidy in 50% of cases. FLC is chromosomally stable as compared to typical HCC. mTOR pathway activation has also been found to play a critical role in 47% of these tumours and EFGR over-expression is also evident. Fibrolamellar carcinomas (FLCs) exhibit a distinctive gross appearance, characterized by a yellow to pale tan colour, with a consistency that can vary from soft to firm and hard. In addition, a central scar is observed in 60-70% of FLC cases. The central scar is typically white or grey in colour and has a fibrous appearance, which is often surrounded by nodular, tumour-like tissue. Its histologic appearance is characterized by large polygonal cells with abundant eosinophilic cytoplasm, large vesiculated nuclei, large nucleoli, and arranged in lamellar bands of collagen fibres. Lamellar bands of fibrosis, consisting of collagen type I, III and IV, have also been identified as a distinctive histologic feature that is observed under low power magnification. Ultrasound, CT and MRI along with image guided biopsy are the primary modalities in diagnosis. Current management options include systemic therapy which has thus far been unremarkable with platinum-based therapies as well combination therapy with interferon alpha-2b being the most successful options. Surgical resection remains the primary treatment modality and there have been no advances in targeted therapies. Although the prognosis for FLC is favourable as compared to other hepatic cancer subtypes such as intrahepatic cholangiocarcinoma, there is a high rate of recurrence ranging from 33% to 100% with a median recurrence-free survival of 20-48 months. As a result of this there is a low overall cure rate associated with this tumour type and much more research is required to gain an in-depth understanding of the molecular mechanisms occurring in order to provide more adequate treatment to patients who suffer from this condition
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review
    Amano, Tsukuru
    Chano, Tokuhiro
    Yoshino, Fumi
    Kimura, Fuminori
    Murakami, Takashi
    [J]. HEALTHCARE, 2019, 7 (03)
  • [42] The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
    Jiang, Hao
    Liao, Jian
    Wang, Liezhi
    Jin, Chong
    Mo, Jinggang
    Xiang, Sheng
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Male Breast: A Review of the Literature and Current State of the Art of Diagnostic Imaging Work-Up
    D'Angelo, Anna
    Portaluri, Antonio
    Caprini, Flavia
    Sofia, Carmelo
    Ferrara, Francesca
    Condorelli, Elvira
    Iaccarino, Ludovica
    Catanzariti, Francesca
    Mancino, Matteo
    Trombadori, Charlotte M. L.
    Belli, Paolo
    Marino, Maria Adele
    [J]. DIAGNOSTICS, 2023, 13 (24)
  • [44] Knowledge and practice on magnitude, diagnosis, treatment and prevention strategies of Hepatocellular Carcinoma in Ethiopia: A Systematic Review
    Mekonnen, Daniel
    Derbie, Awoke
    Biadglegne, Fantahun
    Adem, Yesuf
    Zenebe, Yohannes
    Mekonnen, Hailu
    Gebeyaw, Alemneh
    Shumet, Abebe
    Bereded, Fetlework
    Hailu, Derese
    Feleke, Berhanu Elfu
    Mihret, Adane
    Saek, Ulrich
    [J]. ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT, 2017, 31 (01) : 44 - 56
  • [45] Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review)
    Yang, Shuyue
    Wang, Jiaxin
    Wang, Shidong
    Zhou, Anni
    Zhao, Guiping
    Li, Peng
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 61 (02)
  • [46] Surgical Resection of a Recurrent Hepatocellular Carcinoma with Portal Vein Thrombosis: Is It a Good Treatment Option? A Case Report and Systematic Review of the Literature
    Sena, Giuseppe
    Paglione, Daniele
    Gallo, Gaetano
    Goglia, Marta
    Osso, Mariasara
    Nardo, Bruno
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [47] Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
    Lu, Li-Chun
    Chang, Chun-Jung
    Hsu, Chih-Hung
    [J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2019, 6 : 71 - 84
  • [48] Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review
    Bonosi, Lapo
    Ferini, Gianluca
    Giammalva, Giuseppe Roberto
    Benigno, Umberto Emanuele
    Porzio, Massimiliano
    Giovannini, Evier Andrea
    Musso, Sofia
    Gerardi, Rosa Maria
    Brunasso, Lara
    Costanzo, Roberta
    Paolini, Federica
    Graziano, Francesca
    Scalia, Gianluca
    Umana, Giuseppe Emmanuele
    Di Bonaventura, Rina
    Sturiale, Carmelo Lucio
    Iacopino, Domenico Gerardo
    Maugeri, Rosario
    [J]. LIFE-BASEL, 2022, 12 (03):
  • [49] Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations
    Fancellu, Alessandro
    Sanna, Valeria
    Scognamillo, Fabrizio
    Feo, Claudio F.
    Vidili, Gianpaolo
    Nigri, Giuseppe
    Porcu, Alberto
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (15) : 3517 - 3530
  • [50] Update on diagnosis and treatment of early signet-ring cell gastric carcinoma: A literature review
    Tang, Yun-He
    Ren, Lin-Lin
    Mao, Tao
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, 2023, 15 (04): : 240 - 247